A 48-year-old man with confirmed Meniere disease (low-frequency SNHL, episodic vertigo, tinnitus, aural fullness) has had 3–4 attacks per month over the past 6 months despite salt restriction and fluid management. He is now seeking long-term prophylactic therapy to reduce attack frequency. Which drug is the preferred first-line prophylactic agent?

Explanation

## Prophylactic Management of Meniere Disease ### Stepwise Approach to Meniere Prophylaxis **Key Point:** Prophylaxis in Meniere disease aims to **reduce attack frequency and severity** over weeks to months, distinct from acute attack management. ### First-Line Prophylactic Agents | Agent | Mechanism | Onset | Evidence | Role | |-------|-----------|-------|----------|------| | **Betahistine** | Histamine H₁ agonist; H₃ antagonist → increases inner ear blood flow, reduces endolymphatic pressure | 2–4 weeks | Strong RCTs | **First-line prophylaxis** | | **Thiazide diuretics** | Osmotic diuresis → reduces endolymph volume | 1–2 weeks | Moderate | Alternative first-line | | **Prochlorperazine** | Dopamine antagonist | Minutes (acute) | N/A for prophylaxis | **Acute attacks only** | | **Gentamicin** | Aminoglycoside → ablates vestibular function | Days–weeks | Strong for refractory cases | **Refractory disease** | | **Dexamethasone** | Corticosteroid → anti-inflammatory | Days | Limited evidence | **Intratympanic (refractory)** | ### Why Betahistine Is Correct for Prophylaxis **High-Yield:** Betahistine is the **preferred first-line prophylactic agent** in Meniere disease because: 1. **Mechanism:** Histamine H₁ receptor agonism increases microcirculation in the inner ear; H₃ antagonism reduces histamine release, lowering endolymphatic pressure. 2. **Evidence:** Multiple RCTs demonstrate 40–60% reduction in attack frequency. 3. **Safety:** Well-tolerated with minimal serious adverse effects; no ototoxicity. 4. **Onset:** Takes 2–4 weeks; patient must be counseled about delayed benefit. 5. **Guideline consensus:** Recommended by AAO-HNS and European guidelines as first-line prophylaxis. **Mnemonic:** **BETA** for Betahistine prophylaxis: - **B**etahistine (first-line) - **E**ndolymph pressure reduction - **T**akes 2–4 weeks - **A**ttack frequency ↓ 40–60% **Clinical Pearl:** Betahistine is often given at **16 mg three times daily** (48 mg/day total). Some patients require 8–16 weeks to assess full benefit. ### When to Escalate Beyond Betahistine ```mermaid flowchart TD A[Meniere Disease Prophylaxis]:::outcome --> B[Start: Betahistine 16 mg TDS]:::action B --> C{Response after 8-12 weeks?}:::decision C -->|Good| D[Continue betahistine]:::action C -->|Partial| E[Add thiazide diuretic]:::action C -->|Poor/Refractory| F{Intractable?}:::decision F -->|Yes| G[Intratympanic gentamicin or dexamethasone]:::urgent F -->|No| H[Reassess diagnosis, increase betahistine dose]:::action D --> I[Long-term control achieved]:::outcome E --> J[Improved frequency reduction]:::outcome G --> K[Vestibular ablation or anti-inflammatory effect]:::outcome ``` **Key Point:** Thiazide diuretics (e.g., hydrochlorothiazide 25 mg daily) are an **alternative first-line** if betahistine is contraindicated or ineffective, but betahistine is preferred due to superior evidence and mechanism specificity.